2006 - Drug Discovery Digest

Deep Brain Stimulation Helps Two Patients Walk After Spinal Cord Injury

Drugs.com

DECEMBER 3, 2024

3, 2024 -- In 2006, Wolfgang Jäger was in his 30s when a skiing accident left the young Austrian wheelchair-bound from a spinal cord injury.Fast-forward to today, where an innovative deep-brain stimulation technique is helping the. TUESDAY, Dec.

Young Workers' Injuries Rise After Recreational Marijuana Sales Made Legal

Drugs.com

FEBRUARY 23, 2024

Bureau of Labor statistics for 2006 through 2020 show that legal “recreational marijuana. FRIDAY, Feb. 23, 2024 -- After states legalize the sale of weed for recreational use, on-the-job injuries rise among younger workers, new research shows.U.S.

Research

From Integration to AI: The Data-Driven Future of Market Access

Drug Channels

NOVEMBER 15, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Click here to learn more about NorstellaLinQ , an integrated data asset that combines claims, labs, and EMR data with forecasting, clinical, payer, and commercial intelligence. Read on for their insights. All rights reserved.

Marketing

Marketing International Drugs

Transparency Shocker: Biosimilars Are Getting Cheaper—But Hospitals and Insurers Can Make Them Expensive

Drug Channels

NOVEMBER 4, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. drug channel system is warping hospitals’ incentives to adopt biosimilars, while simultaneously raising costs for commercial plans. The namesake of my alma mater once said: “Sunlight is said to be the best of disinfectants.” All rights reserved.

Biosimilars

Biosimilars Hospitals Pharmacy Drugs

Women in Military More Likely to Suffer Chronic Pain During Wartime

Drugs.com

JULY 8, 2024

MONDAY, July 8, 2024 -- Wartime appears to increase the risk of chronic pain for military women, a new study suggests.Active-duty servicewomen who served between 2006 and 2013 – a period of heightened combat deployments – had a significantly inc.

Inflation-Adjusted U.S. Brand-Name Drug Prices Fell for the Seventh Consecutive Year as a New Era of Drug Pricing Dawns

Drug Channels

JANUARY 7, 2025

Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. New channel modelsincluding smaller PBMs, cost-plus pharmacies, patient-paid discount card prescriptions, and manufacturers direct-to-patient businessesare creating novel paths for drugs that can be sold without gross-to-net bubble distortions.

Pharmacy

Pharmacy Drugs Production

Available for Preorder: The 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

FEBRUARY 26, 2025

Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Email Paula Fein ( paula@drugchannels.net ) if youd like to bundle the report purchase with access to DCIs video webinars. Special preorder and launch pricing discounts will be valid through March 31, 2025. Read on for more details.

Pharmacy

Pharmacy Licensing Licensing Drugs

Bridging the Gap in Patient Support: How GoodRx is Revolutionizing Access to Specialty Meds

Drug Channels

MARCH 7, 2025

Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Divya discusses how integrating digital solutions from GoodRx can enhance engagement, streamline access to therapy, and improve patient outcomes. To learn more, download the GoodRx Yellow Paper: GoodRx Helps Enable Pharmas GTM Strategies.

Therapies

Therapies Marketing Drugs

How the Perfect Storm Will Impact Patient Support Programming in 2025 and Beyond

Drug Channels

NOVEMBER 7, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. To learn more, register for ConnectiveRx’s free webinar on December 11: The Perfect Storm? Patient Support Programming in 2025 and Beyond. Read on for Chris’s insights. All rights reserved. This Feed is for personal non-commercial use only.

Marketing

Marketing Drugs

How the IRA’s Part B Coinsurance Inflation Adjustments Can Raise Seniors’ Drug Costs

Drug Channels

MAY 21, 2025

Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Well unpack the good, the bad, and the ugly of the pharmacy industryand explore what it means for you. This dynamic session will blend expert insights and real-time debate. Hope you can join us! All rights reserved.

Pharmacy

Pharmacy Drugs

How to Run DMC? It’s Tricky – FDA’s New Draft Guidance Provides Updated Recommendations on How to Best Use Data Monitoring Committees in Clinical Trials

FDA Law Blog: Drug Discovery

MARCH 7, 2024

Clissold — The trio of CDER, CBER, and CDRH released a new draft guidance titled “ Use of Data Monitoring Committees in Clinical Trials ” that revises the 2006 guidance “Establishment and Operation of Clinical Trial Data Monitoring Committees” and, when final, will replace the 2006 guidance.

Clinical Trials

Clinical Trials Trials FDA Regulations

As MFP Approaches, Transparency Is More Important Than Ever

Drug Channels

OCTOBER 11, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. To learn more, register for Kalderos’ October 25 webinar Cracking the MFP Code: How Flexible Technology Helps You Navigate an Evolving Landscape. Read on for Angie’s insights. All rights reserved.

Pharmacy

Pharmacy Compliance Drugs

Mapping the Vertical Integration of Insurers, PBMs, Specialty Pharmacies, and Providers: DCI’s 2025 Update and Competitive Outlook

Drug Channels

APRIL 9, 2025

Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. While some major companies have narrowed their focus or unwound previous integration efforts, ongoing consolidation and selective deconsolidation will continue to reshape the healthcare biome by trying to build something epic, block by block.

Specialty Pharmacies

Specialty Pharmacies Pharmacy Drugs

How Large PBMs Make Money Today: A 2025 Drug Channels Update

Drug Channels

MAY 12, 2025

2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Watch the full webinar replay and download the complete slide deck to explore these dynamics in more depth. For a more comprehensive analysis of the forces transforming PBMs, see DCIs 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers.

Pharmacy

Pharmacy Drugs

At the Breaking Point: The Unsustainable Future of Government Drug Discount Programs

Drug Channels

JULY 12, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. To learn more, register for Kalderos’ August 21, 2024, webinar: Revolutionizing Government Discount Programs: Why Traditional Methods Fail. Read on for Gavin’s insights. All rights reserved. This Feed is for personal non-commercial use only.

Government

Government Drugs

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble? (rerun)

Drug Channels

DECEMBER 9, 2024

Read more 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. But whats really going to bake your noodle later: Would the largest PBMs have popped the gross-to-net bubble for Humira if they hadnt been able to profit from the switch? All rights reserved. This Feed is for personal non-commercial use only.

Biosimilars

Biosimilars Production Marketing Drugs

Innovative Models for Improving Access and Visibility for Specialty-Lite and Retail Therapies

Drug Channels

OCTOBER 4, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. To learn more, register for AssistRx's free webinar on October 8: Meet Your Patients Where They Are & Gain Visibility: Even at Retail. Read on for Timothy’s insights. All rights reserved.

Therapies

Therapies Production Drugs

The Promise of a Direct-to-Patient Model—Breaking Down What’s Really Needed for Better Patient Access

Drug Channels

OCTOBER 17, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. They argue that a technology-enabled infrastructure, combined with clinical and reimbursement support specialists, can improve patients' access to new therapies, shorten the time to therapy, and enable better overall clinical outcomes.

Therapies

Therapies Drugs

Can Rite Aid Recover?

Drug Channels

AUGUST 13, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Drug Channels has been tracking retail pharmacies’ economic and business challenges —and Rite Aid’s troubles—for many years. Consider this article to be an opportunity for some fact-based analysis to replace your schadenfreude.

Pharmacy

Pharmacy Drugs

Navigating Market Access Challenges in Life Sciences Commercialization

Drug Channels

MARCH 28, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Bill discusses specialty therapy access barriers, including payer utilization management techniques and “no coverage” policies. Contact Mercalis to learn about their Patient Support Services. Read on for Bill’s insights. All rights reserved.

Marketing

Marketing Science Therapies Production

The Top Pharmacy Benefit Managers of 2024: Market Share and Key Industry Developments

Drug Channels

MARCH 31, 2025

Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. For a deeper dive into the state of the industry, join me this Friday, April 4, 2025, for our live video webinar: PBM Industry Update: Trends, Challenges, and Whats Ahead. P.S. Special launch pricing on our new 2025 Economic Report on U.S.

Pharmacy

Pharmacy Marketing Drugs

Exclusive Report: Manufacturers Identify the Three Critical Drivers of Hub Success

Drug Channels

FEBRUARY 24, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Matt shares three key findings from CareMetx’s exclusive new survey on patient support services for specialty pharmaceuticals. To learn more, download CareMetx’s free 2022 Report - Patient Services Trends. Read on for Matt’s insights. d/b/a Drug Channels Institute.

Pharmaceuticals

Pharmaceuticals Drugs

What Pharma Companies Can Expect From the Influx of Humira Biosimilars

Drug Channels

OCTOBER 14, 2022

Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Steve walks us through the expected Humira biosimilars launches and discusses potential responses from payers. To learn more, check out MMIT’s Strategic Launch Report & Evaluate Forecast solution. Read on for Steve’s insights. d/b/a Drug Channels Institute.

The End of the Blockbuster Era: Unlocking Growth with Direct-to-Patient Commercialization

Drug Channels

MARCH 21, 2025

Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. To learn more about EVERSANA DIRECT Commercialization and how the direct-to-patient model can help you, meet with EVERSANA at the Asembia Summit in Las Vegas. Read on for Greg's insights. All rights reserved.

Pharmacy

Pharmacy Production Drugs

A New Point-of-Prescribing Solution to Help Increase Prescribing Accuracy, Speed to Therapy and Patient Adherence

Drug Channels

JANUARY 13, 2023

Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. He describes CoverMyMeds’ provider alerts solution, which is designed to minimize medication errors. Click here to learn more about CoverMyMeds’ Provider Medication Alerts solution. Read on for Clay’s insights. d/b/a Drug Channels Institute.

Therapies

Therapies Production Drugs

Improve Access, Affordability, and Brand Performance With GoodRx’s Point-of-Sale Rebate Programs

Drug Channels

FEBRUARY 17, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Jim discusses GoodRx Assist , a point-of-sale (POS) rebate program designed to help cash-paying patients start and stay on brand-name medication. Click here to learn more about GoodRx Assist. Read on for Jim’s insights. d/b/a Drug Channels Institute.

Drugs

Strategic planning in ADC development: insights from Lonza

Drug Target Review

JUNE 2, 2025

It was in 2006, when the bioconjugation field – particularly ADCs – was still in its infancy, that Bertholjotti entered this rapidly advancing space. Active in the bioconjugates industry since 2006, Iwan currently builds strategies to advance the development of bioconjugates from preclinical to commercial stages.

Small Molecule

Small Molecule Engineering Therapies Drugs

What Manufacturers Need to Know About Alternative Payment Models

Drug Channels

JULY 15, 2022

Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Carolyn explains the advantages of alternative payment models (APM) for measuring and rewarding value and outcomes in our healthcare system. For more on how APMs measure value, click here to learn about MMIT’s Pulse Analytics Solution. Read on for Carolyn’s insights.

Drugs

Four Keys to Success for Retail and Specialty-Lite Hub Services

Drug Channels

FEBRUARY 23, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. She outlines four success factors for manufacturers that use a digital hub partner. To learn more, register for Phil's upcoming webinar: Improving Access, Coverage, and GTN with a Digital Hub. Read on for Nicole’s insights.

Drugs

Building New Data Connections Helps Brands Lower Adherence

Drug Channels

OCTOBER 1, 2022

Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Kylie explains how new ways of harnessing patient data can transform the way pharmaceutical companies interact with patients and providers—and ultimately help improve adherence. Click here to learn about the ConnectiveRx Enterprise Data Platform. Read on for Kylie’s insights.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceuticals Production Drugs

The New Hub Features Improving Patient Assistance

Drug Channels

JULY 22, 2022

Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Ian shares an overview of The Evolving Role of Hubs and Patient Services , his recent presentation at Informa Connect's Hub and Specialty Model East conference in June. Click here to watch Ian’s full presentation. Read on for Ian’s insights. d/b/a Drug Channels Institute.

Drugs

New Survey Reveals Manufacturers’ Patient Services Priorities for 2024

Drug Channels

FEBRUARY 9, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. As he explains, manufacturers want hub partners that can take a holistic approach and address each patient’s individual needs. Nasir also discusses how hub selection criteria are evolving. Read on for Nasir’s insights. All rights reserved.

Production

Production Research Drugs

Optimizing Access: Balancing Speed-to-Therapy and Gross-to-Net

Drug Channels

JULY 7, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Sahil discusses how manufacturers can balance patients’ access to therapy with gross-to-net (GTN) goals. Visit [link] to learn more about how Phil helps improve the patient experience while managing GTN. Read on for Sahil’s insights. d/b/a Drug Channels Institute.

Therapies

Therapies Drugs

The Evolution of Medical Benefit Contracting: How Pharma Can Prepare

Drug Channels

JANUARY 27, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. He then describes how to automate formulary and medical policies to protect manufacturers from overpayment. Click here to learn about MMIT’s Contract Validation solution. Read on for Saket’s insights. d/b/a Drug Channels Institute.

Copay Comes Full Circle: An Industry Ready for Disruption

Drug Channels

MARCH 8, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. To request an analysis of your copay savings program and learn more about Paysign’s patient affordability solutions, contact affordability@paysign.com or visit paysign.com/rx. Read on for Logan’s insights. All rights reserved.

Drugs

What a Technology-First Approach Really Means for Your Patient Support Program

Drug Channels

MARCH 3, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. To learn more, download AssistRx's free 61-page eBook: Specialty Drug Patient Support Programs: 2022 Progress Report. Read on for Jan’s insights. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Therapies

Therapies Drugs

What Pharmaceutical Manufacturers Value Most from a Hub

Drug Channels

SEPTEMBER 8, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Based on CareMetx research, he outlines the key factors that drug manufacturers value in their hub partners. Learn more by downloading CareMetx’s full report: The Evolving Landscape of Digital Healthcare Hubs. Read on for Nasir’s insights. d/b/a Drug Channels Institute.

Pharmaceuticals

Pharmaceuticals Therapies Production Drugs

How Patient Engagement Can Reduce Brand Launch Risks

Drug Channels

APRIL 12, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. To learn more about enhancing patient engagement and adherence, download CareMetx's new report: Driving Brand Success: Minimize Risk and Capture Missed Value from Patient Engagement and Adherence. Read on for Jessica’s insights.

Drugs

Cell and Gene Therapy Roundup: What the Road to Success Looks Like

Drug Channels

NOVEMBER 11, 2022

Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Click here to learn about AmerisourceBergen’s Cell and Gene Therapy solutions for biopharma companies, providers, and patients. Read on for Lung-I’s insights. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Therapies

Therapies Drugs

Three Digital Intake Strategies For Eliminating Patient Enrollment Forms

Drug Channels

MARCH 22, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. He then explains three ways that specialty pharmaceutical companies can use digital intake strategies to speed patient enrollment. Read on for Adam’s insights. All rights reserved. This Feed is for personal non-commercial use only.

Pharmaceutical Companies

Pharmaceutical Companies Therapies Pharmaceuticals Drugs

Technology’s New Approach: One Gateway to Deliver Comprehensive Patient Support Services

Drug Channels

JUNE 16, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. He then discusses Advanced Gateway, a technology that integrates patient, provider, and manufacturer services. Click here to learn more about how AssistRx’s Advanced Gateway can impact patient support programs. Read on for Derek’s insights. d/b/a Drug Channels Institute.

Engineering

Engineering Drugs

Transforming Medication Access with the Next Generation of Patient Support Services

Drug Channels

DECEMBER 8, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. She describes how CoverMyMeds improves the patient experience by blending technology with human expertise and connection. Click here to learn about CoverMyMed’s next-generation patient support services. Read on for Kelly’s insights. d/b/a Drug Channels Institute.

Therapies

Therapies Production Drugs

The Pulse of Electronic Benefit Verification Solutions: Know the Facts

Drug Channels

SEPTEMBER 16, 2022

Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. He also describes the circumstances where each solution provides the greatest value. To learn more, download AssistRx’s free eBook: Specialty Drug Patient Support Programs: 2022 Progress Report. Read on for Edward’s insights. d/b/a Drug Channels Institute.

Drugs

The Next Great Healthcare Surge: A ‘Diagnosis Explosion’

Drug Channels

AUGUST 19, 2022

Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. He goes on to describe how human contact and support helps patients understand their disease and their treatment plan, thus increasing adherence. Click here to learn how CoverMyMeds’ technology interventions help patients. Read on for John’s insights. d/b/a Drug Channels Institute.

Treatment

Treatment Disease Drugs

Deep Brain Stimulation Helps Two Patients Walk After Spinal Cord Injury

Young Workers' Injuries Rise After Recreational Marijuana Sales Made Legal

Trending Sources

From Integration to AI: The Data-Driven Future of Market Access

Transparency Shocker: Biosimilars Are Getting Cheaper—But Hospitals and Insurers Can Make Them Expensive

Women in Military More Likely to Suffer Chronic Pain During Wartime

Inflation-Adjusted U.S. Brand-Name Drug Prices Fell for the Seventh Consecutive Year as a New Era of Drug Pricing Dawns

Available for Preorder: The 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Bridging the Gap in Patient Support: How GoodRx is Revolutionizing Access to Specialty Meds

How the Perfect Storm Will Impact Patient Support Programming in 2025 and Beyond

How the IRA’s Part B Coinsurance Inflation Adjustments Can Raise Seniors’ Drug Costs

How to Run DMC? It’s Tricky – FDA’s New Draft Guidance Provides Updated Recommendations on How to Best Use Data Monitoring Committees in Clinical Trials

As MFP Approaches, Transparency Is More Important Than Ever

Mapping the Vertical Integration of Insurers, PBMs, Specialty Pharmacies, and Providers: DCI’s 2025 Update and Competitive Outlook

How Large PBMs Make Money Today: A 2025 Drug Channels Update

At the Breaking Point: The Unsustainable Future of Government Drug Discount Programs

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble? (rerun)

Innovative Models for Improving Access and Visibility for Specialty-Lite and Retail Therapies

The Promise of a Direct-to-Patient Model—Breaking Down What’s Really Needed for Better Patient Access

Can Rite Aid Recover?

Navigating Market Access Challenges in Life Sciences Commercialization

The Top Pharmacy Benefit Managers of 2024: Market Share and Key Industry Developments

Exclusive Report: Manufacturers Identify the Three Critical Drivers of Hub Success

What Pharma Companies Can Expect From the Influx of Humira Biosimilars

The End of the Blockbuster Era: Unlocking Growth with Direct-to-Patient Commercialization

A New Point-of-Prescribing Solution to Help Increase Prescribing Accuracy, Speed to Therapy and Patient Adherence

Improve Access, Affordability, and Brand Performance With GoodRx’s Point-of-Sale Rebate Programs

Strategic planning in ADC development: insights from Lonza

What Manufacturers Need to Know About Alternative Payment Models

Four Keys to Success for Retail and Specialty-Lite Hub Services

Building New Data Connections Helps Brands Lower Adherence

The New Hub Features Improving Patient Assistance

New Survey Reveals Manufacturers’ Patient Services Priorities for 2024

Optimizing Access: Balancing Speed-to-Therapy and Gross-to-Net

The Evolution of Medical Benefit Contracting: How Pharma Can Prepare

Copay Comes Full Circle: An Industry Ready for Disruption

What a Technology-First Approach Really Means for Your Patient Support Program

What Pharmaceutical Manufacturers Value Most from a Hub

How Patient Engagement Can Reduce Brand Launch Risks

Cell and Gene Therapy Roundup: What the Road to Success Looks Like

Three Digital Intake Strategies For Eliminating Patient Enrollment Forms

Technology’s New Approach: One Gateway to Deliver Comprehensive Patient Support Services

Transforming Medication Access with the Next Generation of Patient Support Services

The Pulse of Electronic Benefit Verification Solutions: Know the Facts

The Next Great Healthcare Surge: A ‘Diagnosis Explosion’

Stay Connected